PharmaShots | Incisive News in 3 Shots

Subscribe Now

EXPAND

Verily Acquires SignalPath to Expand its Clinical Research Capabilities

Verily Acquires SignalPath to Expand its Clinical Research Capabilities

August 18, 2021

Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

March 31, 2021

Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar- adalimumab) in Australia and Canada

Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar- adalimumab) in Australia and Canada

March 30, 2021

Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities

Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities

March 26, 2021

mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

March 23, 2021

Pfizer's Lorbrena (lorlatinib) Receives FDA's Approval for Expanding its Indication to Treat ALK-Positive Metastatic Lung Cancer

Pfizer's Lorbrena (lorlatinib) Receives FDA's Approval for Expanding its Indication to Treat ALK-Positive Metastatic Lung Cancer

March 4, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us